celagrip

Celagrip is an **interferon inducer** drug primarily studied for its activity as a regulator of **type I interferon (IFN-I) synthesis** and activation of **interferon-stimulated genes (ISGs)** involved in innate immunity. Its mechanism centers on the upregulation of genes such as **ISG15, P53 (TP53), USP18, IFN-α2, and IFN-λ1**, modulating immune responses and impacting reactive oxygen species (ROS) generation. Celagrip has been investigated particularly in hematologic malignancies like **follicular lymphoma** and **Burkitt's lymphoma**, where it demonstrated variable effects on ROS production and gene expression, suggesting immunomodulatory and potential antitumor properties. The drug is administered by treating blood cells ex vivo in research studies, but the precise clinical administration route is not specified in published research[1][5][7].

Brand names

celagrip

Other names

CA